FDA Grants Breakthrough Designation to Litifilimab for Cutaneous Lupus Erythematosus

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to litifilimab (BIIB059), an investigational monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), for the treatment of cutaneous lupus erythematosus (CLE).

Announced by Biogen on January 28, 2026, the designation is intended to expedite the clinical development and review of therapies for serious conditions when preliminary clinical evidence suggests potential for substantial improvement over existing treatments.

"The breakthrough therapy designation for litifilimab illustrates the FDA’s recognition of cutaneous lupus as a serious disease that urgently requires new therapies," said Victoria Werth, MD, MS, a professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, and one of the researchers who is conducting the phase 3 trial.¹ "With topical steroids and antimalarials as the initial therapies for managing CLE and no alternatives specifically approved for CLE, there is a need for effective, targeted treatments, and that could be a drug like litifilimab.”

Cutaneous lupus manifests as photosensitive plaques, rash, pruritus, and potential scarring; it can occur with or without concurrent systemic lupus erythematosus (SLE) and is associated with impaired quality of life and psychosocial burden.^2,3,4 Standard management for CLE continues to rely on topical corticosteroids, antimalarial agents (eg, hydroxychloroquine), and nonspecific immunosuppressants, but these approaches are limited by variable efficacy and safety concerns.^5,6,7

The FDA’s breakthrough designation for litifilimab reflects phase II clinical data from the LILAC study showing reductions in skin disease activity compared with placebo. In this randomized, double-blind, placebo-controlled trial, subcutaneous litifilimab administered in multiple dose levels demonstrated superior efficacy versus placebo in the primary endpoint, measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) at week 16. Despite these promising signals, most secondary endpoints were not formally supportive, and the trial was not powered for longer-term outcomes or comprehensive safety characterization.⁸ The designation also aligns with the FDA’s recognition of CLE as a serious and debilitating condition with high unmet need.

Study Overview and Key Findings

The LILAC trial enrolled adults with histologically confirmed moderate-to-severe CLE, with or without systemic involvement. Participants received subcutaneous litifilimab (50 mg, 150 mg, or 450 mg) or placebo over 16 weeks, with dosing at weeks 0, 2, 4, 8, and 12. The primary analysis applied a dose-response model across treatment arms.⁸

At week 16, litifilimab showed a statistically significant improvement in the primary outcome of CLASI-A reduction compared with placebo, suggesting attenuation of cutaneous disease activity. Safety assessments identified instances of hypersensitivity and herpesvirus infections among litifilimab-treated patients, consistent with immunomodulatory therapy.⁸ Although supportive of activity, these results require confirmation in larger, adequately powered phase III studies with longer follow-up.

The ongoing AMETHYST phase 3 program, now under active enrollment, aims to further evaluate the efficacy and safety of litifilimab in CLE, with data anticipated in 2027. Regulatory filings in additional jurisdictions or for systemic lupus erythematosus are expected to leverage these pivotal trials.

Disease Burden and Unmet Clinical Need

CLE encompasses a constellation of clinical subtypes — acute, subacute, and chronic — each with distinct dermatologic features and potential for irreversible skin damage.¹ Patients often endure pain, itch, photosensitivity, scarring alopecia, hyperpigmentation, and dyspigmentation, which can substantially impair daily functioning and psychological well-being.^3,4 Epidemiologic estimates suggest that CLE affects a significant proportion of individuals with lupus, with prevalence estimates indicating a notable clinical burden in dermatology and rheumatology practices.²

Current therapies focus on symptom management and immunosuppression but lack robust evidence from large, randomized controlled trials specifically in CLE populations.⁵ Moreover, treatment responses are heterogeneous and frequently suboptimal, prompting interest in targeted biologics and novel mechanisms of action that address underlying pathogenic pathways, such as type I interferon signaling.

Mechanism and Developmental Context of Litifilimab

Litifilimab is a humanized IgG1 monoclonal antibody directed against BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). BDCA2 engagement inhibits the production of type I interferons and other proinflammatory mediators implicated in the pathogenesis of lupus-related skin inflammation.^9,10 Type I interferon signaling has been postulated to contribute to both systemic and cutaneous lupus manifestations, and modulation of this axis is an active area of therapeutic investigation.

The investigational profile of litifilimab includes evaluations in both SLE and CLE populations, with prior phase II data in SLE suggesting joint and skin activity, though secondary endpoints and safety findings again underscore the need for larger confirmatory studies.^8,11

Next Steps

The FDA’s Breakthrough Therapy Designation for litifilimab represents a regulatory acknowledgment of unmet medical need in CLE and promising preliminary efficacy. However, designation is not an endorsement of efficacy or safety; it reflects early signals that merit expedited development. Clinicians should interpret these results cautiously; the phase II evidence, while encouraging, is limited by sample size, short duration, and incomplete characterization of safety and long-term outcomes.

Further data from phase III programs such as AMETHYST are necessary to determine whether litifilimab will deliver a clinically meaningful benefit relative to existing therapies. Comparative effectiveness studies, broader safety monitoring, and real-world evidence will be essential to delineate the role of BDCA2 inhibition in the evolving therapeutic landscape for CLE.

References

1. Biogen. Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options | Biogen. Biogen. Published January 28, 2026. Accessed January 28, 2026. https://investors.biogen.com/news-releases/news-release-details/biogens-litifilimab-receives-fda-breakthrough-therapy
2. Werth VP, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 2022;387(16):1528-1531. doi:10.1056/NEJMoa2118024. https://www.nejm.org/doi/full/10.1056/NEJMoa2118024
3. Do Vale ECS, et al. Cutaneous lupus erythematosus: etiopathogenic, clinical, diagnostic and therapeutic aspects. J Autoimmun. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173173/ (PMC)
4. Stull C, et al. Cutaneous involvement in systemic lupus erythematosus. J Rheumatol. 2023. https://www.jrheum.org/content/50/1/27
5. Blake SC, et al. Cutaneous lupus erythematosus: A review of the literature. Int J Womens Dermatol. 2019;5(5):320-329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938925/ (PMC)
6. ClinicalTrials.gov. Study to Evaluate BIIB059 (Litifilimab) in CLE and SLE (NCT02847598). https://clinicaltrials.gov/study/NCT02847598 (ClinicalTrials.gov)
7. Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for CLE. Expert Opin Investig Drugs. 2023. https://pubmed.ncbi.nlm.nih.gov/37148249/ (PubMed)
8. Werth VP, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. PubMed summary. https://pubmed.ncbi.nlm.nih.gov/35939578/ (PubMed)
9. Litifilimab. Wikipedia. https://en.wikipedia.org/wiki/Litifilimab (Wikipedia)
10. Elmgren J. Clinical aspects of CLE. Front Med. 2023. https://www.frontiersin.org/articles/10.3389/fmed.2022.984229/full (Frontiers)
11. Furie RA, et al. Litifilimab in SLE. N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/36069871/ (PubMed)